Eli Lilly (LLY) shares slumped lower Monday after it posted data from a trial of its Zepbound obesity treatment showing patients gained substantial weight when they stopped taking the new drug.
Eli Lilly said patients given regular injections of of trizepatide, which the drugmaker brands as Zepbound, benefited from an average weight loss of around 20.9% from a starting average of around 236.6 pounds over the course of the 36-week study.
However, once the treatment ended and patients were switched to a placebo, they saw an average weight regain of around 14.8% over the following year. Those who continued with the drug lost another 5.5% in weight, according to data from the Surmount-4 study published in the Journal of the American Medical Association.
"Patients, providers and the public do not always understand obesity is a chronic disease that often requires ongoing treatment, which can mean that treatment is stopped once weight goals are met," said Eli Lilly's senior vice president for product development, Jeff Emmick.
"However, studies like Surmount-4 show that continued therapy can help people living with obesity maintain their weight loss."
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.